Skip to content

2-aminothiazoles as therapeutic leads for prion diseases

by Alejandra Gallardo-Godoy, Joel Gever, Kimberly L. Fife, B. Michael Silber, Stanley B. Prusiner, Adam R. Renslo
Journal of Medicinal Chemistry ()
Get full text at journal


2-Aminothiazoles are a new class of small molecules with antiprion activity in prion-infected neuroblastoma cell lines (J. Virol. 2010, 84, 3408). We report here structure-activity studies undertaken to improve the potency and physiochemical properties of 2-aminothiazoles, with a particular emphasis on achieving and sustaining high drug concentrations in the brain. The results of this effort include the generation of informative structure-activity relationships (SAR) and the identification of lead compounds that are orally absorbed and achieve high brain concentrations in animals. The new aminothiazole analogue (5-methylpyridin-2-yl)-[4-(3-phenylisoxazol-5-yl)-thiazol-2-yl]-amine (27), for example, exhibited an EC(50) of 0.94 μM in prion-infected neuroblastoma cells (ScN2a-cl3) and reached a concentration of ∼25 μM in the brains of mice following three days of oral administration in a rodent liquid diet. The studies described herein suggest 2-aminothiazoles as promising new leads in the search for effective therapeutics for prion diseases.

Cite this document (BETA)

Authors on Mendeley

Readership Statistics

64 Readers on Mendeley
by Discipline
67% Chemistry
13% Agricultural and Biological Sciences
9% Biochemistry, Genetics and Molecular Biology
by Academic Status
33% Student > Ph. D. Student
27% Researcher
11% Professor > Associate Professor
by Country
3% United Kingdom
2% Malaysia
2% India

Sign up today - FREE

Mendeley saves you time finding and organizing research. Learn more

  • All your research in one place
  • Add and import papers easily
  • Access it anywhere, anytime

Start using Mendeley in seconds!

Sign up & Download

Already have an account? Sign in